Rotavirus vaccine series completion and adherence to vaccination schedules among infants in managed care in the United States
Rotavirus vaccine series completion and adherence to vaccination schedules among infants in managed care in the United States
复制标题
DOI：
10.1016/j.vaccine.2011.12.077
复制
发表时间：
2012-05-21
期刊：
影响因子：
5.5
通讯作者：
Buikema, Ami R.
中科院分区：
文献类型：
--
作者：
Krishnarajah, Girishanthy;Davis, Elizabeth J.;Buikema, Ami R.
背景：目前在美国批准了两种轮状病毒疫苗：3剂RotaTeq （RV5; Merck & Co., Inc., Whitehouse Station， NJ， USA）接种于2、4和6个月；2剂Rotarix （RV1; GlaxoSmithKline, Research Triangle Park， NC， USA）在2个月和4个月时使用。我们的目的是比较接种这些疫苗的婴儿队列之间轮状病毒疫苗系列的完成情况和给药计划的依从性。方法：在2009年1月1日至2009年6月30日期间接种轮状病毒疫苗系列的1岁以下婴儿在美国健康保险索赔数据中被确定。根据疫苗品牌的使用情况形成队列。对fda批准和acip推荐的协调时间表的系列完成度和依从性进行描述性分析，并使用对数二项模型在调整人口统计学变量的同时估计不同疫苗品牌的系列完成度差异。结果：在RV1和RV5队列的婴儿中（N=55,584）， 84.3%的婴儿完成了整个系列。RV1组比RV5组完成研究的比例更高（91.0%比83.4%;P < 0.001；多变量调整相对危险度1.07;95% CI 1.06-1.08）。在RV1和RV5队列中，分别有75.0%和59.5%的婴儿完全符合fda批准的疫苗给药计划（P < 0.001）；83.3%和76.4%的婴儿完全符合统一计划（P < 0.001）。结论：与接种RV5的婴儿相比，接种RV1的婴儿完成该系列的比例更高，并且对各自fda批准和协调的给药计划的依从性更高。(C) 2011 Elsevier Ltd.版权所有。
Background: Two rotavirus vaccines are currently approved in the United States: 3-dose RotaTeq (RV5; Merck & Co., Inc., Whitehouse Station, NJ, USA) is administered at ages 2, 4, and 6 months; and 2-dose Rotarix (RV1; GlaxoSmithKline, Research Triangle Park, NC, USA) is administered at ages 2 and 4 months. Our objective was to compare rotavirus vaccine series completion and dosing schedule compliance between cohorts of infants who received these vaccines.Methods: Infants aged less than 1 year who initiated a rotavirus vaccine series between 01 January 2009 and 30 June 2009 were identified in US health insurance claims data. Cohorts were formed based on vaccine brand use. Series completion and compliance with the FDA-approved and ACIP-recommended harmonized schedules were analyzed descriptively and a log binomial model was used to estimate the difference in series completion by vaccine brand while adjusting for demographic variables.Results: Among infants in the RV1 and RV5 cohorts (N=55,584), 84.3% completed a full series. A greater proportion of the RV1 cohort than the RV5 cohort completed their series (91.0% vs. 83.4%; P < 0.001; multivariate-adjusted relative risk 1.07; 95% CI 1.06-1.08). In the RV1 and RV5 cohorts, respectively, 75.0% and 59.5% of infants were fully compliant with the FDA-approved administration schedule for their vaccine (P < 0.001); 83.3% and 76.4% of infants were fully compliant with the harmonized schedule (P < 0.001).Conclusions: The proportion of infants that completed the series was greater and compliance with respective FDA-approved and harmonized dosing schedules was higher among infants vaccinated with RV1 than among infants who received RV5. (C) 2011 Elsevier Ltd. All rights reserved.